CAMBRIDGE, Mass., Dec. 18,
2024 /PRNewswire/ -- Akebia
Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical
company with the purpose to better the lives of people impacted by
kidney disease, today announced that John
Butler, Chief Executive Officer, will present at the
43rd Annual J.P. Morgan Healthcare Conference on
Thursday, January 16, 2024 at
7:30 AM PST. Among other business
updates, Mr. Butler will discuss the Vafseo® (vadadustat) U.S.
launch.
A webcast of the presentation can be accessed through the
"Investors" section of Akebia's website at https://ir.akebia.com
following the conference.
The J.P. Morgan Healthcare Conference will take place
January 13-16, 2025 in San Francisco.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. Akebia was
founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334295.html
SOURCE Akebia Therapeutics, Inc.
